Investigational drug · Phase 2
XYA02
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "XYA02"
First trial start
2026
Sep 17, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XYA02", any sponsor or status.
Conditions studied
As listed on its trial records.
- MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- GEJ Adenocarcinoma
- Colorectal Cancer
- Pancreatic Adenocarcinoma
- Gastric Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Ovarian cancer · Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "XYA02" as an intervention, largest first.
XYone Therapeutics, IncIndustry
NCT07670312 · 190 participants (planned) · Start Sep 17, 2026 · Primary completion Sep 15, 2029
Drug: XYA02 · For: MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer and 4 more
Sites: Sydney, Australia; Melbourne, Australia; Perth, Australia · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.